You Gave Us Hope. THANK YOU-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
Comment
Favorite

ikool
11-16

You Gave Us Hope. THANK YOU

CERo Says US FDA Clears Investigational New Drug Application to Launch Leukemia Treatment Trial; Shares Soar

CERo Therapeutics Holdings said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.The company said it expects to start the phase 1 trial in Q1 of 2025.CERo's shares soared past 79% in recent trading.Price: 0.34, Change: +0.15, Percent Change: +79.22

CERo Says US FDA Clears Investigational New Drug Application to Launch Leukemia Treatment Trial; Shares Soar

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":371312213864752,"tweetId":"371312213864752","gmtCreate":1731692115429,"gmtModify":1731692119415,"author":{"id":3571296090030717,"idStr":"3571296090030717","authorId":3571296090030717,"authorIdStr":"3571296090030717","name":"ikool","avatar":"https://static.tigerbbs.com/3e0eb2d4ec1ae628be8e4acc7b5712d4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":72,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>You Gave Us Hope. THANK YOU</p></body></html>","htmlText":"<html><head></head><body><p>You Gave Us Hope. THANK YOU</p></body></html>","text":"You Gave Us Hope. THANK YOU","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/371312213864752","repostId":2483370082,"repostType":2,"repost":{"id":"2483370082","kind":"highlight","weMediaInfo":{"introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"media_name":"MT Newswires Live","id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"pubTimestamp":1731683140,"share":"https://www.laohu8.com/m/news/2483370082?lang=&edition=full","pubTime":"2024-11-15 23:05","market":"us","language":"en","title":"CERo Says US FDA Clears Investigational New Drug Application to Launch Leukemia Treatment Trial; Shares Soar","url":"https://stock-news.laohu8.com/highlight/detail?id=2483370082","media":"MT Newswires Live","summary":"CERo Therapeutics Holdings  said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.The company said it expects to start the phase 1 trial in Q1 of 2025.CERo's shares soared past 79% in recent trading.Price: 0.34, Change: +0.15, Percent Change: +79.22","content":"<html><body><p> CERo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings (CERO) said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.</p><p>The company said it expects to start the phase 1 trial in Q1 of 2025.</p><p>CERo's shares soared past 79% in recent trading.</p><p>Price: 0.34, Change: +0.15, Percent Change: +79.22</p></body></html>","source":"mtnewswires_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERo Says US FDA Clears Investigational New Drug Application to Launch Leukemia Treatment Trial; Shares Soar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERo Says US FDA Clears Investigational New Drug Application to Launch Leukemia Treatment Trial; Shares Soar\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-15 23:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CERo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings (CERO) said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.</p><p>The company said it expects to start the phase 1 trial in Q1 of 2025.</p><p>CERo's shares soared past 79% in recent trading.</p><p>Price: 0.34, Change: +0.15, Percent Change: +79.22</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERO":"CERo Therapeutics Holdings, Inc.","BK4139":"生物科技"},"source_url":"https://www.mtnewswires.com/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2483370082","content_text":"CERo Therapeutics Holdings (CERO) said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.The company said it expects to start the phase 1 trial in Q1 of 2025.CERo's shares soared past 79% in recent trading.Price: 0.34, Change: +0.15, Percent Change: +79.22","news_type":1},"isVote":1,"tweetType":1,"viewCount":75,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":22,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}